As acne affects 742 million patients daily, an alarming 48% are unsatisfied with their current acne treatment.1,2 But the landscape is changing with AviClear by Cutera, the first and original FDA-cleared energy-based device for the treatment of mild, moderate, and severe acne.
AviClear is powered by 1726 nm wavelength laser that targets sebaceous glands and suppresses sebum production. The treatment is effective and safe for all skin tones and Fitzpatrick skin types and is completed with three, 30-minute treatments that are performed about one month apart. It effectively treats all severities and forms of acne including hormonal, cystic and inflammatory. By targeting acne at its source, AviClear helps patients enjoy long-term results and clearer skin without the need for cumbersome prescription medications and home treatment protocols.3
As dermatologists and practitioners well know, the current, traditional acne treatment protocols can be bothersome and frustrating for many patients. Antibiotics may work, but acne often returns once they are no longer taken. Retinoids and other topical prescription medications may effectively treat acne but rely on patient compliance. Isotretinoin is often used when all other treatments have failed, but common side effects like dry skin, rash, irritation, and an increase in the risk of birth defects often leads to patient resistance. AviClear was created to help patients avoid these issues by providing a new solution for acne; something that hasn’t been done in decades.
The proven >1726 nm wavelength selectively delivers energy to the sebaceous gland. The heat damages the sebocytes and suppresses sebum production, while other chromophores and the epidermis remain intact.
Long-term data showed progressive improvement for 24 months after the final treatment with a 97% reduction in ILC5
Clinical trials have been positive with most patients reporting fewer, shorter and less intense acne breakouts following AviClear treatment.4 As shown in the chart, trial results are just as impressive, as 80% of patients saw half their acne resolved three months after their final treatment, 87% reported that half their acne resolved six months after their final treatment and 92% of patients saw at least half their acne resolved at 12 months after their final treatment. Finally, long-term data showed progressive improvement for 24 months after the final treatment with a 97% reduction in ILC (Inflammatory lesion count).5 The pattern of improvement is clear; unlike conventional acne treatments, AviClear patients continue to see results well after their treatment, with no side effects and no prescriptions
Patients are reporting visible improvements soon after final treatment session, with the majority seeing continuing improvement for months after. In addition to results, AviClear’s AviCool sapphire contact skin cooling and sensory controls ensure a tolerable patient experience. This winning combination is indeed putting AviClear in the spotlight as an innovative and effective acne treatment for our time.
AviClear is quickly becoming the new gold standard for acne treatment as dermatologists are reporting that results are comparable to those of isotretinoin but without the issues. There is no downtime, no blood tests, no prescriptions. Patients are confirming their results as over 9 out of 10 self-report as being either satisﬁed or very satisﬁed.3
AviClear has changed the face of acne treatments as forward-thinking dermatologists and practitioners are seeing that the answer is clear. AviClear is becoming a leading acne treatment choice of providers and patients alike. By treating mild to severe acne and meeting patient demand for treatments that are convenient, easy, and safe, providers are truly escorting the future right into their offices.
References: 1. Global Acne Market Report 2016-2026, 2. Hayran Y et al. Factors of affecting adherence and patient satisfaction of treatment: a cross sectional study of 500 patients with ance vulgris J. Dermatol Treat 2021; 32 (1): 64-69, 3. Data on file, Cutera Inc., 4. Data on file. FDA clearance study. Cutera Inc., 5. Data on file. Published Article JCD—Selective photothermolysis with a novel 1726 nm laser beam: A safe and effective solution for acne vulgaris
The above paid-for content was produced by and posted on behalf of the Sponsor. Content provided is generated solely by the Sponsor or its affiliates, and it is the Sponsor’s responsibility for the accuracy, completeness and validity of all information included. MedEsthetics takes steps to ensure that you will not confuse sponsored content with content produced by MedEsthetics and governed by its editorial policy.